Teleflex to Close Minnesota Facility, Cut 101 Jobs Amid Restructuring

Teleflex, a major player in the medical device industry, has announced plans to close its manufacturing facility in Maple Grove, Minnesota, by March 2026. This move, part of a broader restructuring initiative, will result in the layoff of 101 employees.

Facility Closure and Job Cuts

The Maple Grove facility, which specializes in the production of diagnostic and interventional catheters, is set to cease most laboratory and manufacturing operations by June 30, 2025. According to a Worker Adjustment and Retraining Notification (WARN) filing, the majority of layoffs will take effect on July 1, 2025.

This closure is a significant step in Teleflex's ongoing restructuring efforts, which aim to streamline manufacturing operations across the company's portfolio. CEO Liam Kelly previously stated the company's intention to reduce the number of manufacturing facilities from 19 to 7, following the integration of Biotronik's vascular intervention division.

Strategic Restructuring and Company Split

The facility closure comes on the heels of Teleflex's February announcement to split into two separate, publicly traded entities. This strategic move will result in:

1. A new company comprising Teleflex's urology, acute care, and OEM businesses.
2. The remaining company, which will include the vascular access, interventional, and surgical businesses.

Concurrent with this split, Teleflex acquired Biotronik's vascular intervention division, further expanding its portfolio in the medical device sector. The remaining company, which includes the newly acquired Biotronik assets, reported pro forma revenue of $2.1 billion for 2024.

Industry Implications and Future Outlook

The closure of the Maple Grove facility and the broader restructuring efforts at Teleflex reflect ongoing trends in the medical device industry, where companies are increasingly focusing on operational efficiency and strategic realignment. As Teleflex moves forward with its split and integration of Biotronik's assets, the industry will be watching closely to see how these changes impact the company's market position and overall performance in the highly competitive medical technology landscape.